Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arformoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.89 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.89 |
| ▸ | PGR | P06401 | 1/20 | 0.89 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | DRD3 | P35462 | 1/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formoterol SCHEMBL3670606 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL29372718 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL117864 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL3040814 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL1660800 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL1650339 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL15421797 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL31079687 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL82829 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL4084169 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | CTXT PTY LTD (AU) | 2026-05-05 | — | — | US | disclosed |
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4638460-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2025-10-29 | — | — | EP | disclosed |
| EP-4430037-B1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | disclosed |
| US-12384801-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | CTXT PTY LTD. (AU) | 2025-08-12 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250170133-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | MERCK SHARP & DOHME LLC (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2010097172-A1 | NEW TETRAHYDROPYRAZOLO[3,4-C]ISOQUINOLIN-5-AMINE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010069504-A1 | (3-OXO)PYRIDIN-4-YLUREA DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL, S.A. (ES) | 2010-06-24 | — | — | WO | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| CN-100490915-C | Otolaryngological delivery device | SCHERING OY (FI) | 2009-05-27 | — | — | CN | disclosed |
| US-7294345-B2 | Otorhinological delivery device | SCHERING OY (FI) | 2007-11-13 | — | — | US | disclosed |
| CN-1829509-A | Pharmaceutical composition for treating tumors | COMBINATORX INC (US) | 2006-09-06 | — | — | CN | disclosed |
| CN-1767870-A | Otorhinology dosing device | TIMO HAAPAKUMPU HARRI JUKARA J (FI) | 2006-05-03 | — | — | CN | disclosed |
| US-20060067982-A1 | Otorhinological delivery device | TIMO HAAPAKUMPU HARRI JUKARA JUHA ALA -SORVARI HEN (FI) | 2006-03-30 | — | — | US | disclosed |
| WO-2004064912-A1 | AN OTORHINOLOGICAL DELIVERY DEVICE | SCHERING OY (FI) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384801-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | STING1, CGAS, MAVS | ADRB2 586/4885ADRB1 465/4885ADRB3 1305/4885 |
| US-20250170133-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | BTK, SYK, LCK | ADRB2 3386/4885ADRB1 3359/4885ADRB3 3089/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | ADRB2 333/4885ADRB1 494/4885ADRB3 442/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | ADRB2 4125/4885ADRB1 4083/4885ADRB3 3133/4885 |
| US-12415785-B2 | Compound modulators of sting | STING1, IRF3, MAVS | ADRB2 1809/4885ADRB1 1372/4885ADRB3 2020/4885 |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADRB1, ADRB2, ADRA2B | ADRB2 2/4885ADRB1 1/4885ADRB3 5/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | ADRB2 534/4885ADRB1 323/4885ADRB3 400/4885 |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | STING1, CGAS, IRF3 | ADRB2 525/4885ADRB1 461/4885ADRB3 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.